Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Net Income towards Common Stockholders (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Net Income towards Common Stockholders for 10 consecutive years, with $12.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Income towards Common Stockholders rose 134.04% year-over-year to $12.2 million, compared with a TTM value of $83.2 million through Dec 2025, up 178.88%, and an annual FY2025 reading of $83.2 million, up 178.88% over the prior year.
  • Net Income towards Common Stockholders was $12.2 million for Q4 2025 at Zevra Therapeutics, up from -$544000.0 in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $74.7 million in Q2 2025 and bottomed at -$47.7 million in Q1 2021.
  • Average Net Income towards Common Stockholders over 5 years is -$8.0 million, with a median of -$9.1 million recorded in 2021.
  • The sharpest move saw Net Income towards Common Stockholders plummeted 1477.9% in 2021, then surged 474.94% in 2025.
  • Year by year, Net Income towards Common Stockholders stood at -$2.7 million in 2021, then skyrocketed by 340.58% to $6.5 million in 2022, then tumbled by 405.89% to -$19.9 million in 2023, then plummeted by 79.67% to -$35.7 million in 2024, then surged by 134.04% to $12.2 million in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for ZVRA at $12.2 million in Q4 2025, -$544000.0 in Q3 2025, and $74.7 million in Q2 2025.